Clinical Trials Logo

Abortion, Threatened clinical trials

View clinical trials related to Abortion, Threatened.

Filter by:

NCT ID: NCT04788108 Not yet recruiting - Threatened Abortion Clinical Trials

Oral Progesterone for Prevention of Miscarriage in Threatened Abortion

Start date: March 2021
Phase: Phase 4
Study type: Interventional

This study evaluates the effectiveness of oral dydrogesterone in preventing miscarriage in threatened abortion. Half of participants will receive oral dydrogesterone, while the other half will receive oral placebo.

NCT ID: NCT04217200 Completed - Abortion, Complete Clinical Trials

Pregnancy Dating Test - The Fall of hPL in Urine Over Time

Start date: February 19, 2020
Phase:
Study type: Observational

Earlier studies describe the half-life of hPL in serum as being ninety minutes and that the hormone is excreted unchanged in urine; consequently, there is real potential to use the fall in hormone levels in urine to monitor bleeding in pregnancy, the outcome of natural and artificial abortions or placental health. This study will focus on the fall of hPL following delivery by Caesarean section when women have a urinary catheter in place and sampling urine is simple to achieve.

NCT ID: NCT03930212 Completed - Threatened Abortion Clinical Trials

Progesterone Supplementation in Threatened Abortion

Prothreat
Start date: January 1, 2018
Phase: Phase 4
Study type: Interventional

To decide whether progesterone supplementation in threatened abortion is a sound practice.

NCT ID: NCT03797508 Recruiting - Abortion Threatened Clinical Trials

Biochemical Versus Ultrasound Findings as Predictors of Fetal Loss in Cases of First Trimester Threatened Miscarriage

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Threatened miscarriage occurs in about one-fifth of pregnancies with an estimated miscarriage rate of 3-16% after successful demonstration of fetal cardiac activity. Various biochemical markers have been studied previously to predict the outcome of threatened miscarriage; However, the results have been conflicting. Several studies have documented that a slow embryonic heart rate at 6.0-7.0 Weeks' gestation is associated with a high rate of first trimester fetal demise. our aim: To evaluate the accuracy of ultrasound findings in comparison to serum CA125 and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage. Will this pregnancy be continued after the first trimester or not?

NCT ID: NCT03548701 Completed - Clinical trials for Pregnancy Trimester, First

Thromboelastometry Prediction Utility for Risk of Abortion

TEMPURA
Start date: June 4, 2018
Phase:
Study type: Observational

This study will use thromboelastometry in ED patients with vaginal bleeding, as well as healthy pregnant controls, to determine if abnormal results are associated with the presence of vaginal bleeding as well as later complications during pregnancy.

NCT ID: NCT03358940 Completed - Clinical trials for Threatened Miscarriage

Assessment of Non-medical Use of Misoprostol in Case of Miscarriage or Threatened Miscarriage.

MISO
Start date: March 29, 2016
Phase: N/A
Study type: Interventional

Non-medical used of misoprostol for abortion is a growing concern in Guadeloupe. Such situation is reasonable for countries in which abortion is not easy to obtain or prohibited. However regarding the risk of complications, it is less understandable in region like Guadeloupe where legal abortion with medical assistance is accessible for all and free. The aim of the study is to investigate on the amount of misoprostol taken by women in Guadeloupe, by doing an analytical measurement. The aim is to evaluate batter this practice in Guadeloupe, when the main objective of the study is to detect the presence or the absence of misoprostol in the urine sample of the woman coming at hospital for threatened miscarriage or miscarriage complications. Moreover, these abortions can be more important than spontaneous miscarriage.

NCT ID: NCT03320213 Completed - Clinical trials for Threatened Miscarriage in First Trimester

Value of CA125 and Yolk Sac Morphology in Prediction of Pregnancy Outcome in Threatened Miscarriage

Start date: October 1, 2016
Phase: N/A
Study type: Observational

evaluation of serum CA125 level and yolk sac morphology in women with threatened miscarriage is very important to predict pregnancy outcome

NCT ID: NCT03309735 Completed - Clinical trials for Threatened Miscarriage

Non-interventional Study of Therapy for Threatened Miscarriage

Start date: October 16, 2017
Phase: N/A
Study type: Observational

Study the efficacy and safety of therapy for threatened miscarriage with medicinal products Utrogestan (micronized progesterone), 200 mg capsules (Besins Healthcare SA, Belgium), and Duphaston (Dydrogesterone), 10 mg coated tablets (Abbott Healthcare Products B.V., the Netherlands)

NCT ID: NCT02950935 Terminated - Clinical trials for Threatened Abortion in First Trimester

Progesterone in Threatened Abortion

Start date: April 4, 2017
Phase: Phase 3
Study type: Interventional

The main objective of this study will be to assess the efficacy of natural progesterone at a daily dose of 25 mg/bid in the maintenance of early pregnancy in women with symptoms of threatened abortion. The secondary objectives will be the efficacy of progesterone in reducing both pain and uterine contractions.

NCT ID: NCT02690129 Recruiting - Clinical trials for Threatened Miscarriage

Vaginal Progesterone for Treatment of Threatened Miscarriage

VPM
Start date: February 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the efficacy of vaginal micronized progesterone in the treatment of threatened miscarriage. All eligible pregnant women will be randomized to either receive vaginal progesterone or no treatment.Evaluation will be two weeks after intervention, then every 4 weeks up to 28 weeks gestation or termination of pregnancy.